Skip to content

Efficacy and Safety Study of Products Based on Tribulus Terrestris, L. in Men With Oligospermia

Efficacy and Safety Study of Products Based on Tribulus Terrestris, L. in Men With Oligospermia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06260007
Enrollment
204
Registered
2024-02-14
Start date
2024-07-12
Completion date
2026-08-17
Last updated
2025-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oligospermia

Brief summary

Efficacy and Safety of Products Based on Tribulus terrestris, L. in Men with Oligospermia. It is expected that the benefits of investigational products outweigh the risks that will be mitigated or carefully managed by the study team.

Interventions

Tribulus terrestris

OTHERPlacebo

Placebo

Sponsors

Herbarium Laboratorio Botanico Ltda
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
25 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. \- Male; 2. \- Ages 25 and 60; 3. \- Diagnosis of oligospermia; 4. \- With sexual partner; 5. \- Indication of drug treatment with steroid hormones, precursors or analogues.

Exclusion criteria

1. \- Severe oligospermia 2. \- Anatomical change 3. \- Previous treatment for oligospermia or concomitant treatment with steroid, anabolic, hormonal precursors such as testosterone or analogues; 4. \- BMI 35; 5. \- Participant who presents liver enzyme and creatinine values above the upper limit of normality; 6. \- History of testicular cancer, or prostate cancer or any other condition that carries risks in this case increased testosterone; 7. \- Hypersensitivity to any ingredient present in the formulation; 8. \- Any criteria or clinical history that, in the investigator's opinion, could compromise the well-being and participant safety; 9. \- Proven infertility of the partner; 10. \- History of genetic disorder; 11. \- History of psychiatric disorder, serious or decompensated illness or any situation that, Investigator's discretion, puts the participant's safety at risk; 12. \- Active cancer at the discretion of the Investigator; 13. \- Participants with pregnant and breastfeeding partners; 14. \- Cycling and horse riding more than 3 hours per week; 15. \- Alcoholism characterized by the inability to control alcohol consumption according to WHO drinker excessive, whose dependence on alcohol is accompanied by mental, health and physics, relationships with others and social and economic behavior. Source: https://www.cancer.gov/publications/dictionaries/cancerterms/def/alcoholism; 16. \- Smoking greater than half a pack per day or equivalent.

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the effectiveness of each product in men with changes in their spermogram compared to placebo.3 monthsAny improvement in sperm concentration (n/mL)

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026